Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0KWKQC
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
DX126-262
|
|||||
| Synonyms |
DAC-001; DX126 262; Recombinant anti-HER2 antibody-Tub 114
Click to Show/Hide
|
|||||
| Organization |
Hangzhou DAC Biotech Co., Ltd.
|
|||||
| Drug Status |
Phase 2
|
|||||
| Indication |
In total 6 Indication(s)
Gastroesophageal junction cancer [ICD11:2B71]
Phase 2
HER2(+) breast cancer [ICD11:2C60-2C65]
Phase 2
Non-small cell lung cancer [ICD11:2C25]
Phase 2
Urothelial cancer [ICD11:2C9Z]
Phase 2
Breast cancer [ICD11:2C60-2C65]
Phase 1
Gastric cancer [ICD11:2B72]
Phase 1
|
|||||
| Antibody Name |
DX-CHO9
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Tubulysin B derivative
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Special Approval(s) |
Special approval (NMPA)
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.